文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新冠病毒感染后急性期到德尔塔和奥密克戎变异株流行时期的后遗症。

Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras.

机构信息

From the Division of Pharmacoepidemiology (Y.X.), Clinical Epidemiology Center, Research and Development Service (Y.X., T.C., Z.A.-A.), and the Nephrology Section, Medicine Service (Z.A.-A.), Veterans Affairs St. Louis Health Care System, the Veterans Research and Education Foundation of St. Louis (Y.X., T.C., Z.A.-A.), the Department of Medicine, Washington University School of Medicine (Z.A.-A.), and the Institute for Public Health, Washington University in St. Louis (Z.A.-A.) - all in St. Louis.

出版信息

N Engl J Med. 2024 Aug 8;391(6):515-525. doi: 10.1056/NEJMoa2403211. Epub 2024 Jul 17.


DOI:10.1056/NEJMoa2403211
PMID:39018527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11687648/
Abstract

BACKGROUND: Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) can affect many organ systems. However, temporal changes during the coronavirus disease 2019 (Covid-19) pandemic, including the evolution of SARS-CoV-2, may have affected the risk and burden of PASC. Whether the risk and burden of PASC have changed over the course of the pandemic is unclear. METHODS: We used health records of the Department of Veterans Affairs to build a study population of 441,583 veterans with SARS-CoV-2 infection between March 1, 2020, and January 31, 2022, and 4,748,504 noninfected contemporaneous controls. We estimated the cumulative incidence of PASC at 1 year after SARS-CoV-2 infection during the pre-delta, delta, and omicron eras of the Covid-19 pandemic. RESULTS: Among unvaccinated persons infected with SARS-CoV-2, the cumulative incidence of PASC during the first year after infection was 10.42 events per 100 persons (95% confidence interval [CI], 10.22 to 10.64) in the pre-delta era, 9.51 events per 100 persons (95% CI, 9.26 to 9.75) in the delta era, and 7.76 events per 100 persons (95% CI, 7.57 to 7.98) in the omicron era (difference between the omicron and pre-delta eras, -2.66 events per 100 persons [95% CI, -2.93 to -2.36]; difference between the omicron and delta eras, -1.75 events per 100 persons [95% CI, -2.08 to -1.42]). Among vaccinated persons, the cumulative incidence of PASC at 1 year was 5.34 events per 100 persons (95% CI, 5.10 to 5.58) during the delta era and 3.50 events per 100 persons (95% CI, 3.31 to 3.71) during the omicron era (difference between the omicron and delta eras, -1.83 events per 100 persons; 95% CI, -2.14 to -1.52). Vaccinated persons had a lower cumulative incidence of PASC at 1 year than unvaccinated persons (difference during the delta era, -4.18 events per 100 persons [95% CI, -4.47 to -3.88]; difference during the omicron era, -4.26 events per 100 persons [95% CI, -4.49 to -4.05]). Decomposition analyses showed 5.23 (95% CI, 4.97 to 5.47) fewer PASC events per 100 persons at 1 year during the omicron era than during the pre-delta and delta eras combined; 28.11% of the decrease (95% CI, 25.57 to 30.50) was attributable to era-related effects (changes in the virus and other temporal effects), and 71.89% (95% CI, 69.50 to 74.43) was attributable to vaccines. CONCLUSIONS: The cumulative incidence of PASC during the first year after SARS-CoV-2 infection decreased over the course of the pandemic, but the risk of PASC remained substantial even among vaccinated persons who had SARS-CoV-2 infection in the omicron era. (Supported by the Department of Veterans Affairs.).

摘要

背景:严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)感染的急性后期后遗症(PASC)可能影响许多器官系统。然而,在 2019 年冠状病毒病(Covid-19)大流行期间,包括 SARS-CoV-2 的演变,可能会影响 PASC 的风险和负担。在大流行期间,PASC 的风险和负担是否发生了变化尚不清楚。

方法:我们使用退伍军人事务部的健康记录,建立了一个由 441583 名在 2020 年 3 月 1 日至 2022 年 1 月 31 日期间感染 SARS-CoV-2 的退伍军人和 4748504 名同期未感染的对照组成的研究人群。我们估计了在 SARS-CoV-2 感染后 1 年内 PASC 的累积发病率,分为新冠疫情的德尔塔前、德尔塔和奥密克戎时代。

结果:在未接种疫苗的 SARS-CoV-2 感染者中,感染后第 1 年的 PASC 累积发病率在德尔塔前时代为每 100 人 10.42 例(95%置信区间[CI],10.22 至 10.64),在德尔塔时代为每 100 人 9.51 例(95%CI,9.26 至 9.75),在奥密克戎时代为每 100 人 7.76 例(95%CI,7.57 至 7.98)(奥密克戎与德尔塔前时代之间的差异为每 100 人减少 2.66 例[95%CI,2.93 至 2.36];奥密克戎与德尔塔时代之间的差异为每 100 人减少 1.75 例[95%CI,2.08 至 1.42])。在接种疫苗的人群中,在奥密克戎时代,感染后第 1 年的 PASC 累积发病率为每 100 人 5.34 例(95%CI,5.10 至 5.58),在德尔塔时代为每 100 人 3.50 例(95%CI,3.31 至 3.71)(奥密克戎与德尔塔时代之间的差异为每 100 人减少 1.83 例[95%CI,2.14 至 1.52])。与未接种疫苗的人相比,接种疫苗的人在感染后第 1 年的 PASC 累积发病率较低(差异在德尔塔时代为每 100 人减少 4.18 例[95%CI,4.47 至 3.88];在奥密克戎时代为每 100 人减少 4.26 例[95%CI,4.49 至 4.05])。分解分析显示,与德尔塔前和德尔塔时代相比,奥密克戎时代每 100 人在感染后第 1 年减少了 5.23 例(95%CI,4.97 至 5.47)的 PASC 事件;28.11%的减少(95%CI,25.57 至 30.50)归因于与时代相关的影响(病毒和其他时间相关的变化),71.89%(95%CI,69.50 至 74.43)归因于疫苗。

结论:在 SARS-CoV-2 感染后第 1 年,PASC 的累积发病率在大流行期间有所下降,但即使在奥密克戎时代感染 SARS-CoV-2 的接种人群中,PASC 的风险仍然很大。(由退伍军人事务部支持)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/c4257d89fc9e/NEJMoa2403211_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/82c7c7cd5a87/NEJMoa2403211_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/aaff3872cdbe/NEJMoa2403211_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/63f6bdef03c8/NEJMoa2403211_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/c4257d89fc9e/NEJMoa2403211_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/82c7c7cd5a87/NEJMoa2403211_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/aaff3872cdbe/NEJMoa2403211_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/63f6bdef03c8/NEJMoa2403211_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/11687648/c4257d89fc9e/NEJMoa2403211_f4.jpg

相似文献

[1]
Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras.

N Engl J Med. 2024-8-8

[2]
Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post-Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras.

Clin Infect Dis. 2025-4-10

[3]
Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.

Am J Epidemiol. 2024-8-5

[4]
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.

MMWR Morb Mortal Wkly Rep. 2022-2-4

[5]
Postacute sequelae of COVID-19 at 2 years.

Nat Med. 2023-9

[6]
Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves.

J Am Geriatr Soc. 2023-12

[7]
Three-year outcomes of post-acute sequelae of COVID-19.

Nat Med. 2024-6

[8]
Post-acute sequelae of COVID-19 3 to 12 months after infection: Delta vs Omicron.

Int J Infect Dis. 2025-1

[9]
Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study.

Clin Infect Dis. 2025-3-17

[10]
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.

JAMA. 2022-10-18

引用本文的文献

[1]
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.

JAMA Intern Med. 2025-9-2

[2]
Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients.

Biomedicines. 2025-7-23

[3]
Burden of ageing spectrum of diseases in China, 1990-2021: a systematic analysis of global burden of disease study 2021.

Front Public Health. 2025-7-29

[4]
Automatic detection of persistent physiological changes after COVID infection via wearable devices with potential for long COVID management.

Sci Rep. 2025-8-11

[5]
Design and validation of an energy level diary for fatigue management in patients with post-COVID syndrome.

Front Rehabil Sci. 2025-7-21

[6]
Comparing DNA Methylation Landscapes in Peripheral Blood from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Patients.

Int J Mol Sci. 2025-7-10

[7]
Pre-COVID health-related quality of life predicts symptoms and outcomes for patients with long COVID.

Front Public Health. 2025-7-11

[8]
Inflammatory, fibrotic and endothelial biomarker profiles in COVID-19 patients during and following hospitalization.

Sci Rep. 2025-7-10

[9]
Clinical Characteristics and Long-Term Effects of COVID-19 in a Secondary Care Hospital in South India: A Study of Post-acute Sequelae and Pulmonary Outcomes.

Cureus. 2025-6-8

[10]
The short-, medium- and long-term risk and the multi-organ involvement of clinical sequelae after COVID-19 infection: a multinational network cohort study.

J R Soc Med. 2025-7-8

本文引用的文献

[1]
Solving the puzzle of Long Covid.

Science. 2024-2-23

[2]
Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.

Lancet Infect Dis. 2024-3

[3]
Postacute sequelae of COVID-19 at 2 years.

Nat Med. 2023-9

[4]
Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1-13, 2022, to June 7-19, 2023.

MMWR Morb Mortal Wkly Rep. 2023-8-11

[5]
The immunology of long COVID.

Nat Rev Immunol. 2023-10

[6]
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.

BMJ. 2023-4-25

[7]
Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.

JAMA Intern Med. 2023-6-1

[8]
Long COVID: major findings, mechanisms and recommendations.

Nat Rev Microbiol. 2023-3

[9]
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.

Nat Med. 2022-11

[10]
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.

JAMA. 2022-10-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索